Penumbra, Inc. (PEN)
NYSE • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Penumbra, Inc. keeps $9 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 10 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Penumbra’s second fiscal quarter of 2026, reported July 30, 2026, was a mixed print: EPS of $0.88 missed the $1.16 estimate by about 24%, even as revenue of about $390.0 million edged the $389.6 million consensus by roughly 0.1%. Revenue rose about 15% from $339.5 million a year ago, and gross margin held near 68% while operating margin came in around 11%, with gross profit at about $264.9 million and operating income of roughly $41.0 million. Net income fell about 23% to roughly $34.8 million from $45.3 million a year ago, while operating cash flow was $46.1 million. Consensus for the next period calls for EPS of $1.26 on revenue of $401.5 million.
Next report — what to expect
Penumbra, Inc. (PEN) reports on November 4, 2026. Wall Street is looking for EPS of $1.20 on revenue of $401.4 million. For trailing context, revenue grew +14.9% year over year last quarter. PEN has beaten EPS in 6 of 8 most recent quarters, keeping focus on margins and procedure-driven demand.
About Penumbra, Inc.
Penumbra, Inc. develops and sells medical technology for vascular and neuro interventions, trading on the NYSE as PEN. In healthcare, it focuses on devices used to remove clots, treat aneurysms and other lesions, and support neurosurgical evacuation, with $1.4 billion in FY2025 revenue.
Today's Snapshot
PEN closed slightly lower at 324.68, while its sector was weaker. Earnings are due from PEN on 4 November.
Trading Volume
Above 10d avg 321.3K
331.4K
vs S&P 500 Today
Moderate Outperformance
+0.43%
Updated: October 23, 2026 at 20:08 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$319.14 - $322.49Buy
- RSI (14)64.43Neutral
- Stochastic %K (14, 3, 3)89.68Sell
- MACD Level (12, 26)1.18Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.